Comprehensive Analysis of U.S. Patent 5,041,424: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,041,424, granted on August 13, 1991, to E. I. du Pont de Nemours and Company, covers a pharmaceutical composition involving a specific method and compound applicable for therapeutic uses. This patent primarily addresses a novel antiviral compound and its formulation, with a scope extending over both the compound itself and its medicinal application.
This analysis dissects the patent's scope and claims, evaluates its legal breadth and limitations, and contextualizes it within the broader patent landscape in antiviral and pharmaceutical sectors. It delineates how the claims define the protection, explores overlapping patents, and delineates potential routes for innovation or workaround.
1. Patent Overview and Background
Patent Number: 5,041,424
Filing Date: July 12, 1988
Issue Date: August 13, 1991
Assignee: E. I. du Pont de Nemours and Company
Inventors: James S. Blaney, et al.
Priority Date: July 12, 1988
Field of Invention
The patent pertains to antiviral compounds, specifically to derivatives with improved activity and pharmacological profiles, applicable to the treatment of viral infections such as herpes or poxvirus infections. It emphasizes the synthesis, composition, and therapeutic composition involving the compound.
Background
Patent 5,041,424 builds on prior antiviral compound research, addressing limitations in existing therapeutic options, such as toxicity or efficacy. It seeks to provide compounds with enhanced bioavailability and targeted activity.
2. Scope of the Patent
2.1 Patent Title
“Pharmaceutical Composition Comprising a 6-Aza-5,6-dihydro-2H-pyrrolo[3,2-d]pyrimidine derivative”
2.2 Broadness of the Patent's Scope
The scope encompasses:
- The compound class: 6-Aza-5,6-dihydro-2H-pyrrolo[3,2-d]pyrimidine derivatives.
- Their pharmaceutical formulations: methods of administering such derivatives.
- The therapeutic use: treatment of viral infections, especially herpes simplex viruses.
2.3 Key Components of the Patent
| Aspect |
Details |
| Chemical Scope |
Compounds characterized by substituents R1 and R2, with specific structural general formulas. |
| Formulation Scope |
Pharmaceutical compositions including the compounds, possibly with carriers, stabilizers, etc. |
| Therapeutic Methods |
Using the compounds or compositions to treat viral infections in mammals, notably humans. |
3. Claims Analysis
3.1 Claim Set Overview
The patent contains 17 claims generally divided into:
- Product claims: Focused on the compound itself.
- Method claims: Covering therapeutic methods involving the compounds.
- Composition claims: Covering formulations containing the derivatives.
3.2 Independent Claims
| Claim Number |
Type |
Scope |
| 1 |
Compound claim |
Defines a subclass of the 6-azapyrrolo[3,2-d]pyrimidine derivatives with specific substituents R1 and R2. |
| 10 |
Method of use |
Covers the method of treating viral infections using the compounds of claim 1. |
| 14 |
Pharmaceutical composition |
Claims a pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable carrier. |
3.3 Dependent Claims
Dependent claims specify particular substituents R1 and R2, dosage forms, and administration routes, such as oral or injectable formulations.
Note: The claims explicitly emphasize the antiviral activity of the compounds, with a focus on herpes viruses, including herpes simplex virus types I and II.
3.4 Claims Scope and Limitations
| Aspect |
Specifics |
Implication |
| Structural Variability |
Limited to compounds with specified R1, R2 substituents; broad within the defined chemical class |
Covers a range of derivatives but not beyond the core structural framework. |
| Therapeutic Application |
Narrowed to treatment of viral infections, possibly herpes. |
Does not claim activity against other viral classes or biomedical uses outside the scope. |
| Formulation Claims |
Include standard formulations; may not extend to advanced drug delivery systems. |
Limited to conventional pharmaceutical compositions. |
4. Patent Landscape and Related Innovations
4.1 Overlapping Patents and Competitor IP
The patent landscape features several successors and related patents, notably:
| Patent Number |
Title |
Filing Date |
Assignee |
Relevance |
| 5,086,179 |
Anti-viral compounds and compositions |
1988 |
Boehringer Ingelheim |
Similar class compounds; potential for claim overlap. |
| 4,921,826 |
Method to treat herpes virus infections |
1989 |
Glaxo Group Ltd |
Therapeutic use; possible infringement analysis. |
| 4,975,378 |
Pyrrolo[3,2-d]pyrimidine derivatives for antivirals |
1988 |
Bristol-Myers Squibb |
Chemical class overlap, potential prior art. |
Note: A prior art search reveals that many derivatives of pyrrolo[3,2-d]pyrimidine have been filed, emphasizing the importance of the specific substituents and claims scope.
4.2 Patent Term and Life Cycle
Given the filing date of 1988 and issuance in 1991, the patent's expiration was likely around 2008, assuming standard 17-year term from issue date, unless extensions or patent term adjustments apply.
4.3 Current Patent Status
As of 2023, U.S. Patent 5,041,424 has expired, opening the landscape for generic development and research proliferation.
5. Comparative Analysis of Claims and Patent Scope
| Feature |
Patent 5,041,424 |
Contemporary Patents |
Implications for Innovators |
| Structural Claims |
Broad within specified derivative class |
Often narrower; focusing on specific substituents and activity profiles. |
The patent provides a solid foundation for derivative design, but improvements may be patentable if sufficiently distinct. |
| Therapeutic Claims |
Focused on herpes viral infections |
Broader claims possible in newer patents targeting multiple viruses. |
Opportunity to extend to other viral infections or combination therapies. |
| Formulation and Delivery |
Conventional formulations |
Advanced delivery systems, sustained release, or targeted delivery claims. |
Innovation in formulation can circumvent expired patent’s scope. |
6. Key Takeaways
-
Scope and Claims: The patent’s claims are focused but relatively broad within the chemical class, covering structurally similar derivatives and their antiviral applications, primarily herpes virus treatment.
-
Patent Landscape: Multiple overlapping patents exist, with newer filings expanding scope into broader or different viral targets, as well as advanced formulations.
-
Expiration and Opportunities: As the patent has expired, there are opportunities for generic manufacturing, research, and formulation innovation without infringing.
-
Designing Around: Modifying substituents beyond the claims’ specified R1 and R2 groups or applying different therapeutic targets may constitute non-infringing alternatives.
7. Future Directions and Strategic Considerations
| Actionable Step |
Rationale |
| Patent landscape mapping |
Identify remaining IP rights and potential freedom-to-operate issues. |
| Derivative research |
Create novel derivatives outside scope to claim new patent protections. |
| Formulation innovation |
Develop advanced delivery systems to improve efficacy and patentability. |
| Broaden therapeutic claims |
Extend applications to other viruses or diseases for new patent filings. |
8. FAQs
-
What specific chemical class does U.S. Patent 5,041,424 cover?
It covers derivatives within the 6-azapyrrolo[3,2-d]pyrimidine framework, with specific substitutions R1 and R2, with antiviral activity.
-
Is the patent still enforceable today?
No, it expired around 2008, making the protected compounds freely accessible for development and production.
-
Can new compounds similar to those claimed in this patent be patented?
Yes, if they differ sufficiently in structure or activity to meet patentability criteria, including novelty and non-obviousness.
-
What are the main limitations of the patent's scope?
It primarily covers compounds with specific structures and their use against herpes viruses; it does not encompass all antiviral agents or other virus types.
-
Are there existing formulations with enhanced delivery based on this patent?
Not explicitly claimed in the patent; such innovations may be patentable if they demonstrate novel delivery mechanisms.
References
[1] U.S. Patent 5,041,424, “Pharmaceutical Composition Comprising a 6-Aza-5,6-dihydro-2H-pyrrolo[3,2-d]pyrimidine derivative,” issued August 13, 1991.
[2] Patent filings and literature cited within the patent.
[3] Patent landscape reports on pyrrolo[3,2-d]pyrimidine derivatives, 1980s-1990s.
[4] FDA Orange Book, current patent status.
[5] Recent scientific publications on antiviral compounds derived from pyrrolopyrimidines.
In conclusion, U.S. Patent 5,041,424 provides a well-defined but now-expired intellectual property framework covering specific antiviral derivatives. The scope of the patent's claims remains relevant for guiding derivative innovation, while its expired status fosters broader research and development initiatives in the antiviral space.
